Summary & Overview
HCPCS G8585: Anti-lipid Treatment at Discharge
HCPCS Level II code G8585 designates anti-lipid treatment provided at the time of patient discharge. This code captures discharge planning actions that include initiation, prescription, or provision of lipid-lowering therapy intended to reduce cardiovascular risk after an inpatient stay. Nationally, documenting discharge medication management is important for quality measurement, transitional care, and efforts to reduce readmissions tied to medication gaps.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of what the code represents, how it is applied in discharge workflows, and the clinical context for anti-lipid therapy at transitions of care. The publication also summarizes available national benchmarks and policy-relevant considerations where available, such as code usage for quality measurement, common billing scenarios, and alignment with discharge medication reconciliation practices.
The content is intended for clinicians, billing professionals, and health policy analysts seeking a concise briefing on this HCPCS Level II code, its role in transitional care, and the kinds of documentation that typically support its use. Data not provided in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code G8585 represents anti-lipid treatment at discharge. The service type is medication or therapy provided to manage lipid levels in patients at the time of hospital or facility discharge. The typical site of service is hospital inpatient or observation discharge and other inpatient facility discharge settings where clinicians arrange or provide anti-lipid therapy as part of transition-of-care planning.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult recently hospitalized for acute coronary syndrome or ischemic stroke who is being evaluated for discharge medications to reduce LDL cholesterol and cardiovascular risk. During the discharge medication reconciliation visit, the inpatient team or transitional care pharmacist documents initiation or confirmation of an anti-lipid therapy (for example high‑intensity statin, ezetimibe, or PCSK9 inhibitor) to be continued after discharge. The clinical workflow includes review of inpatient lipid panel results, assessment of prior lipid-lowering therapies and adherence, verification of contraindications (for example active liver disease or severe myopathy), selection of an appropriate anti-lipid agent and dose, patient counseling on administration and side effects, and entry of the discharge medication order and instructions into the electronic health record. The billing event for G8585 reflects the discharge anti‑lipid treatment plan recorded by the hospital or transitional care provider and communicated to the patient and outpatient clinicians for continuity of care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of a procedure | When an E/M visit at discharge includes a separate medically necessary immunization or counseling in addition to documenting anti‑lipid therapy |